Multiple therapeutic approaches that target CD38 in multiple myeloma, melanoma and other CD38-associated malignancies are currently investigated, with the prevailing mechanism attributed to antibody-mediated cytolysis and phagocytosis21. The gene discussed is CD38; the disease is melanoma.